International Journal of Drug Delivery Technology
Volume 14, Issue 2

Formulation, Optimisation and Evaluation of Levodopa and Entacapone Loaded Transdermal Patches for the Treatment of Parkinson’s Disease

Akanksha Ghodke*, Surabhi Taose, Priyanka Rathore, Neha Joshi, Aakash Singh Panwar

Institute of Pharmaceutical Sciences, SAGE University, Indore, Madhya Pradesh, India. 

Received: 10th March, 2024; Revised: 25th April, 2024; Accepted: 18th May, 2024; Available Online: 25th June, 2024 

ABSTRACT

Parkinson’s disease is an extrapyramidal motor disorder leading to progressive degeneration of neurons in substantia niagra, pars compacta and the dopaminergic tract. The most promising drugs used to treat Parkinson’s disease, i.e., levodopa and entacapoe have very low oral bioavailability because of first-pass metabolism, therefore to increase the bioavailability of levodopa and entacapone, these were incorporated in transdermal patches. Different formulations of the levodopa and entacapone drugs were prepared with different polymeric ratios, by using the solvent casting method and the formulations were evaluated for in-vitro and in-vivo tests, which focus on drug release and drug excipient compatibilities. Various models were applied to ascertain the kinetics of drug release by using in-vitro release data. Nine formulations were prepared and evaluated out of which F6 was found to be the best formulation, which contained HPMC and ethyl cellulose in the ratio of 2:3. It showed drug release of 99.11% in about 12 hours.

Keywords: Parkinson’s disease, Levodopa, Entacapone, Transdermal patches.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.66

How to cite this article: Ghodke A, Taose S, Rathore P, Joshi N, Panwar AS. Formulation, Optimisation and Evaluation of Levodopa and Entacapone Loaded Transdermal Patches for the Treatment of Parkinson’s Disease. International Journal of Drug Delivery Technology. 2024;14(2):1044-1050.

REFERENCES

  1. Rastogi V, Yadav P. Transdermal drug delivery system: an overview. Asian J Pharma 2012;161-170.
  2. Bhowmik D, Gopinath H, Kumar P , Duraivel S , Kumar S. Controlled release drug delivery system. The Pharma Innovation. 2012; 1(10): 24-30.
  3. Ranade VV, Hollinger Transdermal Drug Delivery system. Drug Delivery Systems. 2nd edition, CRC Press.
  4. Prausnitz M, Langer R. Transdermal drug Nat Biotechnol.2008; 26: 1261–1268. DOI: 10.1038/nbt.1504
  5. Prausnitz Transdermal Drug Delivery. Nature Biotechnology. 2008
  6. Tripathhi KD. Antiparkinson drug. Essentials of Medical 6th edition, Jaypee Brothers Medical Publishers(P) Ltd., 414-421
  7. Jancovic J, Aguilar Current Approaches to the Treatment of Parkinsons Disease. Neuropsychiatric Disease and Treatment. 2008; 4(4): 743-757
  8. Chen J J, Swope D M, Dashtipour K, and Lyons Transdermal Rotigotine: A Clinically Innovative Dopamine-Receptor Agonist for the Management of Parkinson’s Disease. Pharmacotherapy. 2009; 29(12), 1452–1467. DOI:10.1592/phco.29.12.1452
  9. Stefano D, Sozio P, Iannitelli A, and Cerasa L.S. New drug delivery strategies for improved Parkinson’s disease therapy. Expert Opinion on Drug Delivery. 2009; 6(4): 389– DOI:10.1517/17425240902870405
  10. Dhiman S, Singh T G, Rehni Transdermal Patches: A Recent Approach to New Drug Delivery System. International Journal Of Pharmacy and Pharmaceutical Sciences. 2011: 3, 26-34.
  11. Prajapati T., Patel C. G., Patel C. N. Formulation and evaluation of transdermal patches of repaglinide. International Scholarly research notices. 2011, 9
  12. Rajesh A., Gupta A., Maheshwari BS. Formulation and Evaluation of Transdermal Patches of International Journal of Advances in Scientific Research. 2015; 1(01): 38-44, DOI: 10.7439/ijasr
  13. Latheeshjlal L., Moulika G., Soujanya Y. Transdermal Drug Delivery Systems: An Overview. International Journal of PharmTech Research. 2011; 3(4): 2140-2148
  14. Ledeti I, Bolintineanu S, Vlasen G, Circioban D. Compatibility study between antiparkinsonian drug Levodopa and excipients by FTIR spectroscopy, X-ray diffraction and thermal analysis. Journal of Thermal Analysis and Calorimetry. 2017; 130(1), 433–441.
  15. Chaurasia G. A review of pharmaceutical preformulation studies in formulation and development of new drug molecules. International Journal Of Pharmaceutical Sciences And Research. 2017
  16. Kandavilli S. Polymers in transdermal drug delivery systems. Pharmaceutical Technology 2002; 62-78
  17. Ghoshal , Chakrabarty S., Nanda A., Hydroxy Propyl Methyl Cellulose in Drug Delivery, Pelagia Research Library, 2011 2(2): 152-168.
  18. Bhatia , Sachdeva M., Bajpai M. Formulation and Evaluation of Transdermal patch of Pregabalin. International Journal of pharmaceutical Sciences and Research, 2017.
  19. Alkilani Z.. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. 2015; 438-470.
  20. Gungor S., Erdal M. S, Ozsoy Y. Plasticizers in transdermal drug delivery system. Recent Advances in Plastisizers. 2012; DOI: 10.5772/38156
  21. Mathur V., satrawala Y., Raput M. S. Physical and Chemical Permeation Enhancers in Transdermal drug Delivery System. Asian journal of Pharmaceutics. 2010, Vol 4.
  22. Kumar P. Formulation and Evaluation of Entacapone Sustained Release Tablets. The Pharma Innovation Journal. 2014, 3(8): 80-88.
  23. Banerjee S, Chattopadhyay P, Ghosh A, Bhattacharya S, Kundu A, Veer V. Accelerated stability testing of a transdermal patch composed of eserine and pralidoxime chloride for prophylaxis against ( ± )-anatoxin A poisoning. Journal of Food and Drug 2014; 22(2): 264-270. DOI: 10.1016/j.jfda.2014.01.022
  24. Development of Controlled Drug Delivery Systems (CDDS). UKEssays. November 2013. [online].
  25. Chavez E. J., Torres D. R., Cruz R. I. M., Sampere-Morales, Angeles-Anguiano, and Melgoza-Contreras, Nanocarriers for transdermal drug Research and Reports in Transdermal Drug Delivery, 2012, 3. DOI:10.2147/rrtd.s32621
  26. Ahmad MZ, Sabri AHB, Anjani QK, Domínguez-Robles J, Abdul Latip N, Hamid KA. Design and Development of Levodopa Loaded Polymeric Nanoparticles for Intranasal Delivery. Pharmaceuticals (Basel). 2022 Mar 18;15(3):370. doi: 3390/ ph15030370. PMID: 35337167; PMCID: PMC8951268.
  27. Bhowmick , Sengodan T. Mechanism, Kinetics and Mathematical Modelling of Transdermal Permeation- AnUpdated Review. International Journal of research and development in Pharmacy and Life Sciences. 2013; 2 (6): 636-641.
  28. Girjesh V, Panwar AS.Emulgel: A novel technique for transdermal Drug Delivery. Research Journal of topical and Cosmetic Sciences. 2023; 14(1), 20-28, 2023.
  29. Dash S, Murthy PN, Nath L, Chowdhary P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica - Drug 2010; 67(3): 217-223.